European Evidence‐based (S3) Guidelines for the Treatment of Acne
Alexander Nast(Humboldt-Universität zu Berlin), Harald Gollnick(University Hospital Magdeburg), Christos C. Zouboulis(Freie Universität Berlin), A.Y. Finlay(Cardiff University), Berthold Rzany(Austrian Federal Railways), J.L. López‐Estebaranz(Hospital Universitario Fundación Alcorcón), Rūta Gancevičienė(Vilnius University), Adel Sammain(Charité - Universitätsmedizin Berlin), Thierry Simonart(IS practice), Alison Layton(University of York), Stefanie Rosumeck(Charité - Universitätsmedizin Berlin), R. Erdmann(Charité - Universitätsmedizin Berlin), Falk Ochsendorf(University Hospital Frankfurt), Merete Hædersdal(University of Copenhagen), Maja Vurnek Živković(Sisters of Charity Hospital), Cristina Oprica(Karolinska Institutet), Klaus Degitz, Vincenzo Bettoli(University of Ferrara), N. K. Veien, Brigitte Dréno(Nantes Université)
Journal of the European Academy of Dermatology and Venereology
February 1, 2012
Cited by 422
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
|Clinical and Experimental Dermatology|1994|5.5k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k